IDEAYA Biosciences, Inc. $IDYA Shares Acquired by General American Investors Co. Inc.

General American Investors Co. Inc. lifted its position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) by 7.7% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 280,261 shares of the company’s stock after purchasing an additional 20,000 shares during the period. General American Investors Co. Inc.’s holdings in IDEAYA Biosciences were worth $7,626,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also recently added to or reduced their stakes in the company. Daiwa Securities Group Inc. increased its holdings in IDEAYA Biosciences by 16.1% in the second quarter. Daiwa Securities Group Inc. now owns 3,141 shares of the company’s stock valued at $66,000 after buying an additional 436 shares in the last quarter. CWM LLC grew its position in shares of IDEAYA Biosciences by 33.0% during the 2nd quarter. CWM LLC now owns 3,153 shares of the company’s stock valued at $66,000 after acquiring an additional 782 shares during the period. E Fund Management Co. Ltd. raised its holdings in IDEAYA Biosciences by 7.8% in the 2nd quarter. E Fund Management Co. Ltd. now owns 12,225 shares of the company’s stock worth $257,000 after purchasing an additional 881 shares during the period. PNC Financial Services Group Inc. boosted its position in IDEAYA Biosciences by 39.1% during the second quarter. PNC Financial Services Group Inc. now owns 3,344 shares of the company’s stock worth $70,000 after purchasing an additional 940 shares in the last quarter. Finally, Police & Firemen s Retirement System of New Jersey boosted its position in IDEAYA Biosciences by 6.7% during the second quarter. Police & Firemen s Retirement System of New Jersey now owns 18,878 shares of the company’s stock worth $397,000 after purchasing an additional 1,191 shares in the last quarter. 98.29% of the stock is owned by hedge funds and other institutional investors.

IDEAYA Biosciences Stock Down 0.9%

IDEAYA Biosciences stock opened at $34.47 on Tuesday. The company has a fifty day simple moving average of $35.01 and a 200-day simple moving average of $29.41. The firm has a market capitalization of $3.02 billion, a price-to-earnings ratio of -18.53 and a beta of 0.05. IDEAYA Biosciences, Inc. has a 52-week low of $13.45 and a 52-week high of $39.28.

IDEAYA Biosciences (NASDAQ:IDYA) last posted its quarterly earnings results on Tuesday, November 4th. The company reported $1.33 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.12) by $1.45. The business had revenue of $207.83 million for the quarter, compared to analyst estimates of $59.98 million. On average, research analysts anticipate that IDEAYA Biosciences, Inc. will post -3.07 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on IDYA shares. Truist Financial boosted their price objective on IDEAYA Biosciences from $59.00 to $60.00 and gave the company a “buy” rating in a research report on Tuesday, January 6th. The Goldman Sachs Group upped their price objective on shares of IDEAYA Biosciences from $27.00 to $30.00 and gave the stock a “neutral” rating in a research report on Tuesday, October 21st. JPMorgan Chase & Co. lifted their target price on shares of IDEAYA Biosciences from $74.00 to $79.00 and gave the company an “overweight” rating in a research report on Thursday, October 23rd. New Street Research set a $30.00 price target on shares of IDEAYA Biosciences in a research report on Tuesday, October 21st. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of IDEAYA Biosciences in a research note on Thursday. Fifteen research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $46.60.

About IDEAYA Biosciences

IDEAYA Biosciences is a clinical-stage precision oncology company dedicated to the discovery and development of novel therapies that exploit synthetic lethality in cancer cells. By targeting key DNA damage response pathways, the company aims to selectively kill tumor cells exhibiting specific genetic vulnerabilities while sparing healthy tissue. IDEAYA’s pipeline includes small-molecule inhibitors designed to address underserved tumor types, and its lead programs are advancing through Phase 1 and Phase 2 clinical trials in multiple oncology indications.

Central to IDEAYA’s approach is its Modular Approach to Precision (MAP) platform, which integrates proprietary genomic and functional screening technologies to identify critical cancer-specific dependencies.